Viracta Therapeutics, Inc. VIRX
0.01 USD 0.00 (+0.00%)
At closeJul 2, 2026, 4:00 PM EDT
0.07 +0.06 +625.97%
After hours · Jul 2, 4:00 PM ET
0.00978 Day range 0.00978
0.13 52-week range 1.31
- YTD
- -93.92%
- 1 year
- -93.89%
News
globenewswire.com Viracta Therapeutics Announces Wind Down of Operations SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why Triumph Group Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket 
benzinga.com Masimo To Rally More Than 13%? Here Are 5 Top Analyst Forecasts For Friday - benzinga.com Why Evaxion Biotech Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket
globenewswire.com Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket 
globenewswire.com Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) -
zacks.com Here's Why Sunesis (VIRX) Is a Great 'Buy the Bottom' Stock Now Sunesis (VIRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall…
investorplace.com Why Is Viracta Therapeutics (VIRX) Stock Up 42% Today? Viracta Therapeutics (NASDAQ: VIRX ) stock is heading higher on Wednesday after the clinical-stage precision oncology company released its Q2 earnings report. The first bit of news boosting VIRX…
globenewswire.com Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val's substantial…
globenewswire.com Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val's…
benzinga.com Why Digital Turbine Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket 
globenewswire.com Viracta Therapeutics Announces New Employment Inducement Grants SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers…
globenewswire.com Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers…
globenewswire.com Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV + ) peripheral T-cell…
investorplace.com 3 Speculative Penny Stocks Offering High-Upside Potential for Under a Buck There are speculative ideas and then there are penny stocks under $1. Outside of forex trading or high-risk options trades, it generally doesn't get much more treacherous than this space.
globenewswire.com Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers…
globenewswire.com Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma - Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete…
globenewswire.com Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients randomized to either nanatinostat monotherapy…
benzinga.com Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.
globenewswire.com Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV + peripheral T-cell lymphoma supporting its speed to market strategy; topline results from…
globenewswire.com Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial Accelerated pace of enrollment supports speed to market strategy Topline results from Stage 1 expected to be presented in the second quarter of 2024 followed by Stage 2 data in the third quarter of…
globenewswire.com Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers…
globenewswire.com Viracta Therapeutics Provides Clinical Update and Outlook for 2024 Speed to market strategy for Nana-val in patients with relapsed or refractory EBV + peripheral T-cell lymphoma supported by complete enrollment of Stage 1, complete enrollment of Stage 2 anticipated…
globenewswire.com Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma First orphan drug designation for Nana-val granted in EBV + solid tumors Seventh orphan drug designation for Nana-val globally; fifth granted by the FDA SAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) --…
globenewswire.com Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further enhance efficacy through a novel split daily…- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 369 companies hit new 52-week lows.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 100 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 345 companies set new 52-week lows.
benzinga.com Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 116 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 127 companies set new 52-week lows.
benzinga.com 79 Biggest Movers From Yesterday Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying…
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 198 companies reached new 52-week lows.- benzinga.com 68 Biggest Movers From Yesterday Gainers Casa Systems, Inc. (NASDAQ: CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core network functions.
- benzinga.com 34 Stocks Moving In Monday's Mid-Day Session Gainers Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 71 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 209 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's morning trading, 400 companies set new 52-week lows.
- benzinga.com 63 Biggest Movers From Yesterday Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares surged 93.2% to close at $1.70 on Thursday. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.
- benzinga.com 44 Stocks Moving In Thursday's Mid-Day Session Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) jumped 52.3% to $1.3396. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.
- benzinga.com 77 Biggest Movers From Yesterday Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) shares surged 23.7% to close at $12.77. Moxian, Inc. (NASDAQ: MOXC) jumped 23.6% to close at $9.52.
- benzinga.com 56 Biggest Movers From Yesterday Gainers Bridgford Foods Corporation (NASDAQ: BRID) shares surged 46.2% to close at $20.74 on Tuesday.
- benzinga.com 70 Biggest Movers From Yesterday Gainers Pandion Therapeutics, Inc. (NASDAQ: PAND) shares surged 133.4% to close at $59.81 on Thursday after the company announced it will be acquired by Merck for $60 per share in cash.